V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320004212 | 320002591 | 1.79 | 70.5 | Disease modification (D) | null | 2014-10-20 | Cisplatin + Docetaxel +Fluorouracil | 01 | N | 320022270 | CISPLATIN + GEMCITABINE |
| 320004213 | 320002592 | 1.61 | 54.45 | Palliative (P) | 2016-12-11 | 2016-12-15 | Carboplatin + Liposomal Doxorubicin | null | null | 320022339 | DOXORUBICIN |
| 320004214 | 320002593 | 1.72 | 0 | Adjuvant (A) | 2017-05-25 | 2017-06-01 | Imatinib 400mg | 2 | N | 320022352 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004215 | 320002594 | 1.7 | 89.5 | Neo-adjuvant (N) | 2014-06-28 | 2014-07-19 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320022357 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004216 | 320002595 | 1.72 | 95.9 | Palliative (P) | 2015-03-18 | 2015-03-18 | CAPECITABINE + CETUXIMAB + CISPLATIN | 02 | N | 320022359 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320004217 | 320002595 | null | 67 | Adjuvant (A) | null | 2016-05-31 | Cisplatin + Docetaxel +Fluorouracil | null | null | 320022359 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004218 | 320002596 | 1.66 | 82.1 | Disease modification (D) | 2017-06-05 | 2017-06-24 | CETUXIMAB + RT | N | N | 320022413 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004219 | 320002597 | -1 | 85.8 | Palliative (P) | 2017-11-18 | 2017-11-25 | CISPLATIN + GEMCITABINE | 02 | N | 320022416 | ICON8B TRIAL |
| 320004220 | 320002598 | null | 68.8 | Neo-adjuvant (N) | 2015-10-23 | 2015-12-04 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320022426 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320004221 | 320002598 | 1.63 | 56 | Neo-adjuvant (N) | 2013-04-01 | 2013-04-13 | PCV | N | N | 320022426 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320004222 | 320002598 | 1.7 | 70.3 | Palliative (P) | 2015-11-08 | 2017-02-12 | Cisplatin + Vinorelbine (IV) | 02 | N | 320022426 | CISPLATIN + PEMETREXED |
| 320004223 | 320002599 | null | 55.2 | Adjuvant (A) | 2018-06-28 | 2018-07-16 | DE-ESCALATE TRIAL | N | Y | 320022484 | CISPLATIN + FLUOROURACIL + RT |
| 320004224 | 320002599 | 1.6 | 51.4 | Palliative (P) | 2017-08-28 | 2017-09-15 | Cisplatin + Docetaxel +Fluorouracil | Y | N | 320022484 | CISPLATIN + FLUOROURACIL + RT |
| 320004225 | 320002599 | null | null | Palliative (P) | null | 2018-09-14 | CISPLATIN + FLUOROURACIL + RT | N | N | 320022484 | COMPARE TRIAL |
| 320004226 | 320002600 | 1.68 | 85.7 | Palliative (P) | 2016-07-17 | 2016-07-22 | CARBOPLATIN + ETOPOSIDE | 02 | N | 320022561 | IPILIMUMAB + NIVOLUMAB |
| 320004227 | 320002600 | 1.72 | 68 | Curative (C) | 2015-10-11 | 2015-10-17 | CISPLATIN + ETOPOSIDE | N | Y | 320022561 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004228 | 320002601 | null | 82.6 | Palliative (P) | 2018-03-24 | 2018-04-14 | Cetuximab + Radiotherapy Maint | 02 | N | 320022617 | CARBO + FLUOROURACIL |
| 320004229 | 320002602 | 1.6 | 51.4 | null | 2016-08-17 | 2016-08-31 | Bevacizumab + CARBOPLATIN + GEMCITABINE | Y | N | 320022635 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 320004230 | 320002603 | 1.8 | 88.1 | Palliative (P) | 2016-03-11 | 2016-04-11 | Capecitabine + Cisplatin | N | N | 320022645 | CARBOPLATIN + CETUXIMAB + FU |
| 320004231 | 320002603 | 1.69 | 112.8 | Palliative (P) | 2016-06-02 | 2016-06-16 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320022645 | CABAZITAXEL |
| 320004232 | 320002604 | 1.79 | 76 | Adjuvant (A) | null | 2017-09-22 | CISPLATIN + DOCETAXEL + FLUOROURACIL | null | null | 320022762 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004233 | 320002605 | 1.64 | 88.2 | Disease modification (D) | 2017-11-30 | 2017-12-16 | CARBOPLATIN + RT | N | N | 320023058 | CAPECITABINE + CARBOPLATIN |
| 320004234 | 320002606 | 1.8 | 56.2 | Neo-adjuvant (N) | 2018-08-11 | 2018-10-02 | Capecitabine + Cisplatin | N | N | 320023262 | BCG |
| 320004235 | 320002607 | null | 56.7 | Palliative (P) | 2018-04-12 | 2018-04-25 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 320023286 | IRINOTECAN + MDG |
| 320004236 | 320005165 | 1.55 | 42.2 | Disease modification (D) | 2016-02-03 | 2016-02-16 | Carboplatin + Pemetrexed | N | N | 320023308 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320004237 | 320002608 | 1.71 | 97 | null | null | 2017-06-10 | Cisplatin+Gemcitabine (Days 1&8&15) | N | N | 320023381 | PEMBROLIZUMAB |
| 320004238 | 320002609 | 1.7 | 73 | Palliative (P) | 2016-12-12 | 2016-12-17 | Carboplatin + Etoposide iv&po | N | N | 320023410 | BCG |
| 320004239 | 320002609 | null | 87 | Palliative (P) | 2016-09-13 | 2016-10-05 | Cetuximab + Radiotherapy Load | N | N | 320023410 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004240 | 320002609 | 1.7 | 57.4 | Palliative (P) | 2019-01-08 | 2019-01-08 | Carboplatin + Pemetrexed | 01 | N | 320023410 | NOT MATCHED |
| 320004241 | 320002610 | 1.57 | 59 | null | 2017-09-30 | 2017-10-13 | CISPLATIN + GEMCITABINE | N | N | 320023556 | PEMBROLIZUMAB |
| 320004242 | 320002611 | null | 110 | null | 2013-07-09 | 2013-07-09 | Capecitabine + Cisplatin | N | null | 320023579 | FLUOROURACIL + MITOMYCIN + RT |
| 320004243 | 320002612 | 1.71 | null | Palliative (P) | 2014-08-18 | 2014-08-20 | ECX | 2 | N | 320023626 | CARBO + FLUOROURACIL |
| 320004244 | 320002613 | null | 66 | Adjuvant (A) | 2014-10-23 | 2014-11-18 | Bevacizumab 15mg/kg | N | Y | 320023668 | IPILIMUMAB |
| 320004245 | 320002614 | 1.69 | 78 | Palliative (P) | 2018-08-30 | 2018-09-16 | Ipilimumab | N | N | 320023759 | PEMBROLIZUMAB |
| 320004246 | 320002615 | 1.63 | 110 | Palliative (P) | 2016-09-21 | 2016-09-25 | Bevacizumab 7.5mg/kg | Y | null | 320023822 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320004247 | 320002616 | 1.69 | 85.7 | Adjuvant (A) | null | 2016-10-18 | Trial Unspecified | N | N | 320023880 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004248 | 320002617 | 1.63 | 85.2 | Palliative (P) | 2017-03-03 | 2017-03-07 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | 320023932 | CARBOPLATIN + LIPOSOMAL DOX |
| 320004249 | 320002617 | null | 146 | Adjuvant (A) | 2013-12-09 | 2013-12-09 | Cetuximab 7 day (Cycle 1) | Y | N | 320023932 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004250 | 320002618 | 1.68 | null | Palliative (P) | 2015-03-20 | 2015-04-03 | Cisplatin+Gemcitabine (gallbladder) | null | N | 320024242 | CISPLATIN + FLUOROURACIL + RT |
| 320004251 | 320005168 | 1.78 | null | Adjuvant (A) | 2015-08-01 | 2015-10-10 | CISPLATIN + GEMCITABINE | null | Y | 320024256 | CETUXIMAB + RT |
| 320004252 | 320002619 | 1.76 | 79.4 | Neo-adjuvant (N) | 2015-04-29 | 2015-05-06 | CETUXIMAB | N | N | 320024308 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004253 | 320002619 | null | null | null | 2017-02-16 | 2017-02-16 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | null | 320024308 | CARBOPLATIN + ETOPOSIDE |
| 320004254 | 320002620 | null | 48 | Palliative (P) | 2014-10-29 | 2014-11-07 | CAPECITABINE + OXALIPLATIN | N | N | 320024471 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004255 | 320005170 | 1.59 | 76.9 | Adjuvant (A) | 2017-01-19 | 2017-04-02 | Bevacizumab+Carbo+Pacliaxel | 02 | N | 320024630 | CARBOPLATIN + ETOPOSIDE |
| 320004256 | 320002621 | 1.7 | 58.9 | null | 2016-06-30 | 2016-07-02 | Docetaxel 75mg/m2 (21 day) | N | null | 320024642 | POUT TRIAL |
| 320004257 | 320002622 | 1.78 | 73.6 | null | null | 2019-05-10 | CETUXIMAB | N | null | 320024715 | CARBOPLATIN + ETOPOSIDE |
| 320004258 | 320002623 | 1.7 | 81.2 | Palliative (P) | 2015-12-07 | 2015-12-09 | Folfirinox | 01 | N | 320024806 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004259 | 320005171 | null | 9 | Palliative (P) | 2019-02-23 | 2019-02-23 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320024890 | CISPLATIN + PACLITAXEL |
| 320004260 | 320002624 | 1.67 | 55.2 | Curative (C) | 2017-12-05 | 2017-12-07 | Cetuximab 7 day (Cycle 1) | 02 | N | 320024980 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320004261 | 320002625 | 1.76 | 87.5 | Neo-adjuvant (N) | 2017-06-10 | 2017-06-21 | Atezolizumab | Y | N | 320025052 | CISPLATIN + DOCETAXEL + FLUOROURACIL |